Abstract
In this study, we evaluated the clinical usefulness of yokukansankachimpihange, which is expected to be effective for controlling chronic excitation symptoms, in AD patients. The subjects were 25 outpatients with AD. All subjects demonstrated a nervous predisposition and were obsessively self-concerned, frequently complaining of symptoms including easy fatigue, and all were readily excitable. As the test drug, yokukansankachimpihange (Kracie) was prescribed for 6 weeks in principle. Significant improvements were observed in the Kampo-based diagnosis of the symptoms as well as itching and irritation scores on VAS, and scores on Skindex 16 compared with before treatment. Based on the findings of this study, yokukansankachimpihange is considered to control itching or skin-specific symptoms that affect the quality of life in AD patients by suppressing emotional reactions that exacerbate the symptoms.
